Consumer Discretionary · Services-Educational Services

CVSA Covista Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 730464118 filings
Russell 2000

CVSA at a glance

Covista Inc. (CVSA, SEC CIK 730464) filed its latest 10-K annual report on August 6, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 19, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended June 30, 2026 (FY2026), Covista Inc. (CVSA) reported revenue of $2.0 billion (up 9.3% from FY2025) and net income of $251.6 million. Diluted EPS was $7.04.
  • As of September 30, 2026, 32 institutional investment managers tracked by SignalX reported holding Covista Inc. (CVSA) shares worth $2.0 billion in 13F-HR filings.
  • In the last 90 days, CVSA insiders reported 0 open-market purchases ($0) and 3 open-market sales ($1.3M) on Form 4, a net sale of $1.3M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2026
$2.0B
+9.3% vs prior year
Insiders · 90 days
0 buys · 3 sells
Net −$1.3M
13F holders
32 funds
$2.0B · +0 vs prior quarter
Latest 8-K
Nov 19, 2026
Item 8.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Jun 30, 2026

Full analysis →

Business Overview

  • Core business: Largest U.S. healthcare educator with 5 accredited institutions delivering nursing, medical, veterinary, social sciences education on campuses and online
  • New emphasis: "Purpose at Scale" strategy focusing on expanding healthcare education access, employer integration, technology, and operational excellence
  • Strategic shift: Expanded medical education in the U.K. via AUC satellite campus partnership with University of Lancashire (since 2019)
  • Quantitative highlight: 10,680 total employees as of June 30, 2026, spanning full-time staff and professors across all segments
  • Noteworthy fact: Fiscal year 2022 ED composite financial responsibility score dropped to 0.2, resulting in provisional Title IV certifications with $202.6M in surety-backed letters of credit

Management Discussion & Analysis

  • Revenue $1,954.1M, up 9.3% YoY ($165.8M increase) driven by all segments: Chamberlain +3.4%, Walden +16.1%, Medical and Veterinary +8.1%
  • Operating margin 19.6% vs 19.1%, adjusted operating margin 21.5% vs 20.7%; net income $251.6M up 6.1%, adjusted net income $294.7M up 15.3%
  • Best segment: Walden adjusted operating income $239.7M, +30.6% YoY; Worst: Chamberlain adjusted operating income $143.6M, down 6.3%
  • Cash flow: Operating cash flow $470.8M (+$137.1M); Capex $77.7M; Share repurchases $239.9M; Dividends not mentioned
  • Outlook/risk: Management highlights focus on enrollment growth, cost control, capital structure optimization; risks include economic changes impacting liquidity and earnings

Risk Factors

  • Regulatory risk: U.S. Department of Education Borrower Defense to Repayment regulations, potential liability and required $500M letters of credit limit under credit agreement
  • Geopolitical/macroeconomic threat: Operations exposed to natural disasters, political disruptions, armed conflicts in U.S. West Coast, Gulf States, Caribbean impacting campuses
  • Operational/supply chain risk: State governments may limit clinical placement affiliations for medical schools, restricting enrollment and growth potential
  • Competitive disruption risk: Increasing competition from traditional colleges' growing online learning and technology-enabled programs threatens enrollment and tuition rates
  • Financial/structural risk: Potential goodwill and intangible asset impairment up to $1.7B combined due to market cap decline or adverse operating results

AI summary of the CVSA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes from 2026 Form 10-K risk factors

Management Discussion & Analysis

  • Revenue $511.5M, up 10.7% YoY from $462.3M, driven by growth across all segments
  • Operating margin 19.2% vs 18.5%; adjusted operating margin 20.8% vs 19.5%
  • Best performer Walden: revenue $216.7M, up 14.1%; worst Chamberlain margin: 13.9% vs 14.3%
  • Cash $222.2M vs $406.3M; operating cash flow $114.3M vs $130.6M
  • Capital deployment: $163.0M debt repayment, $81.0M repurchases, $37.6M capital expenditures
  • Outlook: focus on post-licensure enrollment; headwinds from marketing, labor, credit-loss, and growth-investment costs

AI summary of the CVSA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 19, 2026Full analysis →

Item 8.01: Other Events

  • Updated legal opinion supports potential issuance and sale of common stock under the Plan
  • Exhibit 5.1 addresses legality of shares issuable pursuant to the Plan
Filed Nov 13, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Board committee assignments effective November 11, 2026, adding Emily Chiu to Academic Quality and Audit and Finance
  • Leslie Storms added to Compensation and External Relations, expanding director oversight across key governance functions

Item 5.07: Submission of Matters to a Vote of Security Holders

  • All 11 director nominees elected through the 2027 annual meeting, preserving board continuity
  • Shareholder approval for PwC as independent auditor for 2027, reducing auditor-change uncertainty
Filed Oct 29, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q1 FY27 revenue $511.5M, up 10.7%, with adjusted EPS $2.19, up 25.1%, signaling strong operating momentum
  • Adjusted EBITDA $131.2M, up 17.1%, with margin expanding to 25.6% from 24.2%

Item 2.02: Results of Operations and Financial Condition

  • Press release announces Covista’s first-quarter fiscal 2027 academic, operating and financial results
  • Results cover the quarter ended before October 29, 2026, with substantive metrics in Exhibit 99.1

AI summaries of CVSA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CVSA

Don't miss the next CVSA filing

  • Alerts as it files. A push when CVSA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CVSA, by share count.
  • Ask anything. An AI agent that reads every CVSA filing and answers with sources.

CVSA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Betz MichaelFNov 13, 2026$118.17
Beard, Stephen W.FNov 13, 2026$118.17
Liles ScottFNov 13, 2026$118.17
Gangadharan ManjunathFNov 13, 2026$118.17
BECK DOUGLAS G.FNov 13, 2026$118.17
Phelan Robert J.FNov 13, 2026$118.17
Betz MichaelFNov 12, 2026$119.00
BURKE WILLIAM WFNov 12, 2026$119.00

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2024FY2025FY2026
Profitability
Revenue-$1.8B$2.0B
Operating Income$217.1M$341.5M$383.4M
Net Income$136.8M$237.1M$251.6M
Op. Margin-19.1%19.6%
Net Margin-13.3%12.9%
Balance Sheet
Total Assets-$2.8B$3.0B
Equity-$1.4B$1.4B
ROE-16.5%17.4%
Per Share
EPS-$6.18$7.04
Cash Flow
Operating CF$295.8M$337.9M$470.4M
CapEx$48.9M$50.3M$77.7M

Source: XBRL data in Covista Inc. (CVSA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CVSA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CVSA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202632$2.03B
Q2 202632$2.50B
Q1 202633$2.25B
Q4 202530$1.89B
Q3 202531$2.91B
Q2 202531$2.47B
Q1 202528$1.39B
Q4 202424$1.07B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 241 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CVSA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 19, 2026Analysis-
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
8-KNov 13, 2026Analysis-
4Nov 13, 2026--

Related Consumer Discretionary companies

All Consumer Discretionary →

CVSA SEC filings: frequently asked questions

Are CVSA insiders buying or selling?

In the last 90 days, Covista Inc. (CVSA) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $1.3 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CVSA stock?

As of September 30, 2026, the largest Covista Inc. (CVSA) holders among the 13F filers tracked by SignalX were BlackRock ($628.7 million), Vanguard Portfolio Management LLC ($277.3 million), Dimensional Fund Advisors ($226.7 million), Vanguard Capital Management LLC ($180.3 million), State Street Corp ($168.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CVSA's revenue in fiscal year 2026?

For the fiscal year ended June 30, 2026 (FY2026), Covista Inc. (CVSA) reported revenue of $2.0 billion (up 9.3% from FY2025) and net income of $251.6 million. Diluted EPS was $7.04. The figures come from the XBRL data in the 10-K.

What are the main risks in CVSA's latest 10-K?

In the 10-K filed August 6, 2026, Covista Inc. (CVSA) flagged: Regulatory risk: U.S. Department of Education Borrower Defense to Repayment regulations, potential liability and required $500M letters of credit limit under credit agreement. Geopolitical/macroeconomic threat: Operations exposed to natural disasters, political disruptions, armed conflicts in U.S. West Coast, Gulf States, Caribbean impacting campuses. (AI summary of the Risk Factors section.)

What did CVSA report in its latest 8-K?

Covista Inc. (CVSA) filed an 8-K on November 19, 2026 reporting Item 8.01 (Other Events). Updated legal opinion supports potential issuance and sale of common stock under the Plan.

What are the latest CVSA SEC filings?

Covista Inc. (CVSA) filed its latest 10-K annual report on August 6, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 19, 2026 and a Form 4 insider filing on November 17, 2026.

What is CVSA's SEC CIK number?

Covista Inc. (CVSA)'s SEC Central Index Key (CIK) is 730464. EDGAR lists every CVSA filing under that number.

Ask anything about CVSA

The research agent reads CVSA's filings, financials, insider trades and 13F holders, then answers with sources.